The definitive agreement grants AbbVie access to ImmunoGen’s antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx), which received accelerated approval from the US Food and Drug Administration last year to treat platinum-resistant ovarian cancer.
ADCs are a new class of cancer therapies designed to precisely target and kill tumour cells while sparing healthy ones.
Ovarian cancer is the leading cause of death from gynaecological cancers in the US, and approximately 20,000 patients are diagnosed with the disease each year.
